Krka Group H1 2025 slides: Record sales and profit amid Russian ruble volatility

Slovenian pharmaceutical company Krka Group reported record first-half 2025 results, with sales exceeding €1 billion for the first time at €1,048.5 million (+6% YoY) and net profit rising 11% to €246.7 million. This strong performance, driven by volume growth and significant positive currency effects from the Russian ruble, led the company to confirm its full-year 2025 guidance of over €2 billion in sales and approximately €365 million in net profit. Despite these robust figures and strong profitability margins, Krka's stock traded down 1.2% following the announcement.

Analysis

Krka Group (LJSE:KRK) delivered record first-half 2025 results, with sales surpassing €1 billion for the first time in a half-year period to reach €1,048.5 million, a 6% year-over-year increase. Net profit climbed 11% to €246.7 million, driven by a 4% rise in sales volume and a significant positive impact from foreign exchange movements. The appreciation of the Russian ruble was a material contributor, accounting for €48.1 million in positive FX differences. This performance supported improved profitability metrics, including an EBITDA margin of 28.9% and a return on equity of 20.8%. Growth was geographically concentrated in Eastern Europe, its largest market, which saw an 11% sales increase, while Overseas Markets and Germany reported declines of 16% and 25%, respectively. The company's financial position remains robust, with an 80% equity-to-asset ratio, and it continues to deliver strong shareholder returns through an 8.25% dividend yield and an active share buyback program. Despite the strong headline figures and a confirmation of full-year 2025 guidance, the company's stock fell 1.2% following the announcement, suggesting potential investor concerns over the quality of earnings given the heavy FX influence or specific regional weaknesses.

Key Decisions for Investors

• Investors should weigh the company's strong fundamental performance and confirmed guidance against the market's negative reaction, which may indicate concerns about the sustainability of currency-driven profit growth.
• Given the material impact from the Russian ruble, any position should be monitored with close attention to FX market volatility, as a reversal of the ruble's strength would pose a significant headwind to future earnings.
• For income-oriented investors, Krka's strong balance sheet, 8.25% dividend yield, and consistent share buybacks offer an attractive capital return profile, though the stock's valuation at a P/E of 16.11 should be considered.
• Look ahead to the Q3 2025 results in November, which will include an updated Development Strategy for 2026-2030, providing crucial long-term visibility beyond the current operating cycle.